Effects of the glucocorticoid agonist, RU28362, and the antagonist RU486 on lung phosphatidylcholine and antioxidant enzyme development in the genetically obese Zucker rat
Effects of the glucocorticoid agonist, RU28362, and the antagonist RU486 on lung phosphatidylcholine and antioxidant enzyme development in the genetically obese Zucker rat
The biochemical maturation of the lung in late gestation and in the young animal is regulated by glucocorticoids. The present study was aimed at dissociating the different glucocorticoid receptor sites involved in these regulatory functions. The obese Zucker rat was selected as a model for this study as it exhibits hypersensitivity to glucocorticoid hormone action by virtue of its elevated receptor numbers and activity. Two synthetic steroid analogues were administered to obese animals; RU28362, a specific type II receptor agonist, and the type II antagonist RU486. RU28362 promoted a strong catabolic effect, which was associated with reduced food intake and the abolition of growth in the rats. The agonist, RU28362, attenuated developmental increases in antioxidant enzyme activities, and altered the growth of the tissue. At the age studied, development of the lung phosphatidylcholine (PC) system was almost complete, but RU28362 increased disaturated PC 16:0/16:0 concentrations by almost 2-fold, and altered the molecular composition of total pulmonary PC. RU486 attenuated the growth of the rats and reduced their food intake. Treatment with the type II antagonist attenuated lung growth and increased the activities of pulmonary copper zinc (Cu/Zn) and manganese (Mn) superoxide dismutases. RU486 had no effect on lung PC concentrations and molecular composition. The data suggest a role for type I glucocorticoid receptors in the regulation of the antioxidant enzyme system in the lung, as type II antagonism will channel endogenous glucocorticoid binding to the type I site. Type II receptor binding would appear to play a role in regulating the lung PC content.
543-551
Hunt, A.
95a3e223-da96-40e7-b47d-27dce014e305
Kelly, F.J.
8eda554f-c23c-4321-b5e2-b99a72dfd0aa
Langley, S.C.
94f4c1b1-0dbe-4bd4-8e2f-bba55a0f72ee
Postle, A.D.
0fa17988-b4a0-4cdc-819a-9ae15c5dad66
Rickett, G.W.M.
47456ffe-0548-4ead-887d-0bd94f048c4e
York, D.A.
bf72052a-83b4-404b-984c-2846eab86750
9 February 1993
Hunt, A.
95a3e223-da96-40e7-b47d-27dce014e305
Kelly, F.J.
8eda554f-c23c-4321-b5e2-b99a72dfd0aa
Langley, S.C.
94f4c1b1-0dbe-4bd4-8e2f-bba55a0f72ee
Postle, A.D.
0fa17988-b4a0-4cdc-819a-9ae15c5dad66
Rickett, G.W.M.
47456ffe-0548-4ead-887d-0bd94f048c4e
York, D.A.
bf72052a-83b4-404b-984c-2846eab86750
Hunt, A., Kelly, F.J., Langley, S.C., Postle, A.D., Rickett, G.W.M. and York, D.A.
(1993)
Effects of the glucocorticoid agonist, RU28362, and the antagonist RU486 on lung phosphatidylcholine and antioxidant enzyme development in the genetically obese Zucker rat.
Biochemical Pharmacology, 45 (3), .
(doi:10.1016/0006-2952(93)90125-G).
Abstract
The biochemical maturation of the lung in late gestation and in the young animal is regulated by glucocorticoids. The present study was aimed at dissociating the different glucocorticoid receptor sites involved in these regulatory functions. The obese Zucker rat was selected as a model for this study as it exhibits hypersensitivity to glucocorticoid hormone action by virtue of its elevated receptor numbers and activity. Two synthetic steroid analogues were administered to obese animals; RU28362, a specific type II receptor agonist, and the type II antagonist RU486. RU28362 promoted a strong catabolic effect, which was associated with reduced food intake and the abolition of growth in the rats. The agonist, RU28362, attenuated developmental increases in antioxidant enzyme activities, and altered the growth of the tissue. At the age studied, development of the lung phosphatidylcholine (PC) system was almost complete, but RU28362 increased disaturated PC 16:0/16:0 concentrations by almost 2-fold, and altered the molecular composition of total pulmonary PC. RU486 attenuated the growth of the rats and reduced their food intake. Treatment with the type II antagonist attenuated lung growth and increased the activities of pulmonary copper zinc (Cu/Zn) and manganese (Mn) superoxide dismutases. RU486 had no effect on lung PC concentrations and molecular composition. The data suggest a role for type I glucocorticoid receptors in the regulation of the antioxidant enzyme system in the lung, as type II antagonism will channel endogenous glucocorticoid binding to the type I site. Type II receptor binding would appear to play a role in regulating the lung PC content.
This record has no associated files available for download.
More information
Published date: 9 February 1993
Identifiers
Local EPrints ID: 469641
URI: http://eprints.soton.ac.uk/id/eprint/469641
ISSN: 0006-2952
PURE UUID: 2ddb01ff-dd08-4afa-9a80-69f5b2d64f4b
Catalogue record
Date deposited: 21 Sep 2022 16:58
Last modified: 17 Mar 2024 02:41
Export record
Altmetrics
Contributors
Author:
A. Hunt
Author:
F.J. Kelly
Author:
S.C. Langley
Author:
G.W.M. Rickett
Author:
D.A. York
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics